In fairness, if there's someone who knows about investing in a cash-incinerator, it is you (and col, gavvy, baz, barman).
From FY21-23, your company burnt just a smidge under $230M USD on 'operations' (note, this doesn't even include paying interest costs or rent). How many patients did you recruit during that time? Does generating assay data really cost that much? Cynata seemed to produce the relevant potency data for less that 1% of the cost.
Good luck to you, champ
Ann: First Patient Treated in Phase 2 GvHD Trial, page-9
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.015(9.09%) |
Mkt cap ! $40.67M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.0¢ | 17.5¢ | $29.91K | 170.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35924 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 27622 | 2 |
View Market Depth
| Last trade - 15.57pm 28/07/2025 (20 minute delay) ? |
| CYP (ASX) Chart |